Continue Reading Below Advertisement Regeneron Narrowed Its Full-year 2016 Guidance For Eylea Sales.

Eylea sales growth slowing More From He Made 21,078% Buying Amazon. Heres His New Pick Regeneron reported revenue in the third quarter of $1.22 billion, up 7% year over year. for Eylea made up 70% of total revenue. The good news is that the eye-disease drug saw sales climb 16% compared to the prior-year period, to $854 million. The bad news is that sales growth appears to be slowing. In the second quarter, sales for Eylea were up nearly 27% from the same quarter in 2015. That was slower than the drug’s first-quarter year-over-year sales growth of 44%. Continue Reading Below ADVERTISEMENT Regeneron narrowed its full-year 2016 guidance for Eylea sales. company now expects 23% to 25% growth over 2015.

For the original version including any supplementary images or video, visit

Leave a Reply

Your email address will not be published. Required fields are marked *